23andMe Lays Off 40% of Staff, Shuts Drug Development Business
The genetics company is closing a unit that was once seen as core to its future.
Read more at The Wall Street Journal
-
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
Business - Inc. - November 12 -
DNA-testing site 23andMe to lay off 40% of its workers
Top stories - BBC News - November 12 -
23andMe to lay off 40% of its workforce as stock price plummets
Top stories - CBS News - November 12 -
Rare and classic cars shut off busy London street
Top stories - BBC News - November 2 -
Motion picture academy lays off staff at archive and library amid broader restructuring
Entertainment - Los Angeles Times - October 31 -
AMD will lay off nearly 1,000, or 4% of staff, as AI competition heats up
Tech - VentureBeat - November 13 -
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
Business - MarketWatch - November 12 -
23andMe cuts 40% of its workforce and discontinues therapeutics division
Health - ABC News - November 12 -
What happens to customer data as 23andMe goes out of business?
Top stories - CBS News - November 12
More from The Wall Street Journal
-
Boohoo Changes Chairman as Frasers Calls For Removal
Business - The Wall Street Journal - 1 hour ago -
Resolute Mining Says CEO, Employees Released From Detention in Mali
Business - The Wall Street Journal - 2 hours ago -
JD Sports Expects Profit at Lower End of Guidance
Business - The Wall Street Journal - 2 hours ago -
Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio
Business - The Wall Street Journal - 3 hours ago -
Julius Baer Assets Rise as Inflows Accelerate
Business - The Wall Street Journal - 3 hours ago
